MA49478B1 - Nouveaux conjugués de montélukast et de peptides - Google Patents

Nouveaux conjugués de montélukast et de peptides

Info

Publication number
MA49478B1
MA49478B1 MA49478A MA49478A MA49478B1 MA 49478 B1 MA49478 B1 MA 49478B1 MA 49478 A MA49478 A MA 49478A MA 49478 A MA49478 A MA 49478A MA 49478 B1 MA49478 B1 MA 49478B1
Authority
MA
Morocco
Prior art keywords
peptide
montelukast
compound
containing compound
formula
Prior art date
Application number
MA49478A
Other languages
English (en)
Other versions
MA49478A (fr
Inventor
Ming Gu
Bengt Ingemar Samuelsson
Original Assignee
Enlitisa Shanghai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enlitisa Shanghai Pharmaceutical Co Ltd filed Critical Enlitisa Shanghai Pharmaceutical Co Ltd
Priority claimed from PCT/CN2019/105832 external-priority patent/WO2020052677A1/fr
Publication of MA49478A publication Critical patent/MA49478A/fr
Publication of MA49478B1 publication Critical patent/MA49478B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un composé contenant un peptide qui comprend un constituant peptidique, lequel est une séquence d'acides aminés constituée de 2 à 45 acides aminés, ledit constituant peptidique étant lié de manière covalente à un ou plusieurs composés de formule (i), r1 étant sélectionné dans le groupe constitué par -c(ch3)2oh, -coch3, -c(ch3)=ch2 et -c(ch3)2h, et n représentant 0, 1 ou 2, ainsi que des régioisomères, des stéréoisomères, et des sels pharmaceutiquement ou cosmétiquement acceptables dudit composé contenant un peptide. Le composé de formule i est de préférence le montélukast, le montélukast styrène ou le montélukast styrène hydrogéné. Le composé contenant un peptide est particulièrement utile dans le traitement de l'inflammation, y compris les plaies, les hémorroïdes, les brûlures, le psoriasis, l'acné, la dermatite atopique, la rhinite allergique, la conjonctivite allergique, la bronchopneumopathie chronique obstructive, les maladies inflammatoires intestinales (telles que la rectocolite hémorragique). Le composé contenant un peptide est également utilisable dans le traitement de la fibrose pulmonaire idiopathique.
MA49478A 2018-09-14 2019-09-14 Nouveaux conjugués de montélukast et de peptides MA49478B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018105703 2018-09-14
PCT/CN2019/105832 WO2020052677A1 (fr) 2018-09-14 2019-09-14 Nouveaux conjugués de montélukast et de peptides

Publications (2)

Publication Number Publication Date
MA49478A MA49478A (fr) 2020-03-19
MA49478B1 true MA49478B1 (fr) 2023-06-28

Family

ID=87758679

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49478A MA49478B1 (fr) 2018-09-14 2019-09-14 Nouveaux conjugués de montélukast et de peptides

Country Status (1)

Country Link
MA (1) MA49478B1 (fr)

Also Published As

Publication number Publication date
MA49478A (fr) 2020-03-19

Similar Documents

Publication Publication Date Title
MX2021002657A (es) Nuevos conjugados de montelukast y péptidos.
Ferrari et al. Purinergic signaling in scarring
AU2011316690B2 (en) Cyclosporin analogs
NO20065107L (no) PGD2 reseptor antagonister for behandling av inflammatoriske sykdommer
MX2022003057A (es) Nuevos peptidos.
JP2021525803A (ja) カンナビノイド及びそれらの使用
US20150374699A1 (en) Novel uses
JP5913651B2 (ja) 疼痛および他の疾患の処置のための化合物および方法
AU2015296675B2 (en) Cyclic urea compounds as Granzyme B inhibitors
MA49478B1 (fr) Nouveaux conjugués de montélukast et de peptides
Wang et al. Hydrogen sulfide restores cardioprotective effects of remote ischemic preconditioning in aged rats via HIF-1α/Nrf2 signaling pathway
Wu et al. Unlocking antibacterial potential: key-site-based regulation of antibacterial spectrum of peptides
Meng et al. Injury of cell tight junctions and changes of actin level in acute lung injury caused by the perfluoroisobutylene exposure and the role of Myosin light chain kinase
Nogueira et al. Evaluation of aortic remodeling in apolipoprotein E-deficient mice and renovascular hypertensive mice
Ryu et al. Antimicrobial and anti-inflammatory effects of cecropin A (1-8)–Magainin2 (1-12) hybrid peptide analog P5 against Malassezia furfur infection in human keratinocytes
WO2016015159A1 (fr) Composés d'indoline en tant qu'inhibiteurs du granzyme b
MX2025005720A (es) Inhibidores de la tirosina-cinasa 2 (tyk2)
He et al. Expanding the antimicrobial spectrum of lugdunin: Discovery of multi-cationic derivatives of lugdunin with antimicrobial activity against gram-positive and gram-negative bacteria
Skibba et al. An orally bioavailable BRD4 inhibitor disrupts expansion of a pathogenic epithelial-mesenchymal niche in bleomycin-induced fibrosis
Zhang et al. Thymopentin improves the survival of septic mice by promoting the production of 15-deoxy-prostaglandin J2 and activating the PPARγ signaling pathway
CN101981190A (zh) 用于治疗勃起功能障碍的巴西漫游蜘蛛的毒素
AU2005276117C1 (en) Peptide inhibitors for mediating stress responses
WO2015144977A1 (fr) Modulateurs de trpa1
WO2019143145A1 (fr) Composition pour le traitement d'une inflammation cutanée, comprenant de la résolvine d2 en tant que principe actif
Díaz-Peña et al. Rat aorta relaxation induced by the venom of Poecilotheria regalis involves the activation of the NO/cGMP pathway